4.8 Article

Kisspeptin-10, a KISS1-Derived Decapeptide, Inhibits Tumor Angiogenesis by Suppressing Sp1-Mediated VEGF Expression and FAK/Rho GTPase Activation

期刊

CANCER RESEARCH
卷 69, 期 17, 页码 7062-7070

出版社

AMER ASSOC CANCER RESEARCH
DOI: 10.1158/0008-5472.CAN-09-0476

关键词

-

类别

资金

  1. National Cancer Institute/NLH [1R01CA106479]
  2. Science and Technology Commission of Shanghai Municipality [06DZ22923]

向作者/读者索取更多资源

Kisspeptin-10 (Kp-10), a decapeptide derived from the primary translation product of KISS1 gene, has been reported previously to be a key hormone for puberty and an inhibitor for tumor metastasis via the activation of G protein-coupled receptor 54. However, whether Kp-10 inhibits angiogenesis, which is critical for tumor growth and metastasis and other human diseases, is still unknown. Here we show that Kp-10 significantly inhibits human umbilical vein endothelial cell (HUVEC) migration, invasion, and tube formation, key processes in angiogenesis. Using chicken chorioallantoic membrane assay and vascular endothelial growth factor (VEGF)-induced mouse corneal micropocket assay, we show that Kp-10 inhibits angiogenesis in vivo. Furthermore, Kp-10 inhibits tumor growth in severe combined immunodeficient mice xenografted with human prostate cancer cells (PC-3) through inhibiting tumor angiogenesis, whereas Kp-10 has little effect on the proliferation of HUVECs and human prostate cancer cells. In deciphering the underlying molecular mechanisms, we show that Kp-10 suppresses VEGF expression by inhibiting the binding of specificity protein I to VEGF promoter and by blocking the activation of c-Src/focal adhesion kinase and Rac/Cdc42 signaling pathways in HUVECs, leading to the inhibition of tumor angiogenesis. [Cancer Res 2009;69(17):7062-70]

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Chemistry, Medicinal

Synthesis of heterocyclic ring-fused tricyclic diterpene analogs as novel inhibitors of RANKL-induced osteoclastogenesis and bone resorption

Gao Wei, Yalan Wu, Xiao-Long He, Ting Liu, Mingyao Liu, Jian Luo, Wen -Wei Qiu

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2017)

Article Biochemical Research Methods

Identification of Genes Involved in Breast Cancer Metastasis by Integrating Protein-Protein Interaction Information with Expression Data

Xin Tian, Mingyuan Xin, Jian Luo, Mingyao Liu, Zhenran Jiang

JOURNAL OF COMPUTATIONAL BIOLOGY (2017)

Article Cell Biology

Loss of Lgr4 inhibits differentiation, migration and apoptosis, and promotes proliferation in bone mesenchymal stem cells

Peng Sun, Kunhang Jia, Chunbing Zheng, Xinlei Zhu, Jing Li, Liang He, Stefan Siwko, Feng Xue, Mingyao Liu, Jian Luo

JOURNAL OF CELLULAR PHYSIOLOGY (2019)

Correction Chemistry, Multidisciplinary

Electrospun Micropatterned Nanocomposites Incorporated with Cu2S Nanoflowers for Skin Tumor Therapy and Wound Healing (vol 11, pg 11337, 2017)

Xiaocheng Wang, Fang Lv, Tian Li, Yiming Han, Zhengfang Yi, Mingyao Liu, Jiang Chang, Chengtie Wu

ACS NANO (2019)

Article Immunology

Lipid Receptor G2A-Mediated Signal Pathway Plays a Critical Role in Inflammatory Response by Promoting Classical Macrophage Activation

Qing Li, Chunlei Feng, Lingyun Li, Guiliang Xu, Haijuan Gu, Shiqiang Li, Dali Li, Mingyao Liu, Shuhua Han, Biao Zheng

Summary: This study demonstrates the important role of Lp-PLA(2) in controlling inflammatory macrophage polarization in autoimmune encephalomyelitis and multiple sclerosis. Lp-PLA(2) affects M1 function through lysophosphatidylcholine-mediated pathways and G2A receptor guidance, which could potentially lead to new therapeutic approaches for MS and other inflammatory disorders.

JOURNAL OF IMMUNOLOGY (2021)

Article Chemistry, Medicinal

Design, Synthesis, and Bioevaluation of 2-Aminopteridin-7(8H)-one Derivatives as Novel Potent Adenosine A2A Receptor Antagonists for Cancer Immunotherapy

Fazhi Yu, Chenyu Zhu, Shuyin Ze, Haojie Wang, Xinyu Yang, Mingyao Liu, Qiong Xie, Weiqiang Lu, Yonghui Wang

Summary: Compound 57 demonstrates potential as a novel A(2A) receptor antagonist in cancer immunotherapy, enhancing T cell activation and inhibiting adenosine levels in the tumor microenvironment.

JOURNAL OF MEDICINAL CHEMISTRY (2022)

Article Cardiac & Cardiovascular Systems

Nidogen-2 is a Novel Endogenous Ligand of LGR4 to Inhibit Vascular Calcification

Yufei Chen, Chenfeng Mao, Rui Gu, Rujia Zhao, Weihao Li, Zihan Ma, Yiting Jia, Fang Yu, Jian Luo, Yi Fu, Jinpeng Sun, Wei Kong

Summary: Nidogen-2 is an endogenous ligand of LGR4 that inhibits vascular calcification by activating a specific signaling pathway.

CIRCULATION RESEARCH (2022)

Article Cell Biology

Activation of orphan receptor GPR132 induces cell differentiation in acute myeloid leukemia

Chunyang Yi, Jiacheng He, Dan Huang, Yumiao Zhao, Chan Zhang, Xiyun Ye, Ying Huang, Ruth Nussinov, Junke Zheng, Mingyao Liu, Weiqiang Lu

Summary: Activation of the orphan GPCR GPR132 induces cell differentiation in acute myeloid leukemia (AML) and the natural product 8-gingerol is found to be a potential GPR132 agonist, promoting differentiation and reducing colony formation in AML cell lines.

CELL DEATH & DISEASE (2022)

Article Multidisciplinary Sciences

Cryo-EM structure of the human adenosine A2B receptor-Gs signaling complex

Ying Chen, Jinyi Zhang, Yuan Weng, Yueming Xu, Weiqiang Lu, Wei Liu, Mingyao Liu, Tian Hua, Gaojie Song

Summary: This study presents the structures of the human adenosine A2B receptor (A2BR) bound to its agonists NECA and BAY60-6583, elucidating the orthosteric binding pockets and their subtle differences. Selectivity is mainly determined by regions extended from the orthosteric pocket, and the key determinants for BAY60-6583's selectivity against A2BR are identified. This study provides a better understanding of ligand selectivity in the adenosine receptor family and offers a structural template for the development of A2BR ligands for related diseases.

SCIENCE ADVANCES (2022)

Letter Oncology

C-terminal variants of the P2X7 receptor are associated with prostate cancer progression and bone metastasis - evidence from clinical and pre-clinical data

Haiping Song, Hector Manuel Arredondo Carrera, Alexandria Sprules, Ying Ji, Tongsong Zhang, Jiepei He, Eleanor Lawrence, Alison Gartland, Jian Luo, Ning Wang

CANCER COMMUNICATIONS (2023)

Article Chemistry, Medicinal

Discovery of a Potent and Oral Available Complex I OXPHOS Inhibitor That Abrogates Tumor Growth and Circumvents MEKi Resistance

Peng He, Juanjuan Feng, Xinting Xia, Yue Sun, Jia He, Tian Guan, Yangrui Peng, Xueli Zhang, Mingyao Liu, Xiufeng Pang, Yihua Chen

Summary: HP661 is a highly effective OXPHOS inhibitor that can inhibit mitochondrial oxygen consumption in high OXPHOS lung cancer cells. It also shows significant sensitivity in MEK inhibitor-resistant lung cancer cells and has therapeutic efficacy against high OXPHOS lung cancer.

JOURNAL OF MEDICINAL CHEMISTRY (2023)

Article Chemistry, Medicinal

Discovery of Pyridinone Derivatives as Potent, Selective, and Orally Bioavailable Adenosine A2A Receptor Antagonists for Cancer Immunotherapy

Chenyu Zhu, Shuyin Ze, Ronghui Zhou, Xinyu Yang, Haojie Wang, Xiaolei Chai, Meimiao Fang, Mingyao Liu, Yonghui Wang, Weiqiang Lu, Qiong Xie

Summary: Recent studies and clinical evidence have shown that adenosine A2A receptor (A2AR) antagonists have great potential as novel approaches for cancer immunotherapy. Through the screening of a compound library, a pyridinone hit compound with weak A2AR antagonistic activity was identified, and further studies led to the discovery of a series of pyridinone derivatives with strong potency. Compound 38 demonstrated potent A2AR antagonistic activity, good metabolic stability, and excellent oral bioavailability, and also effectively enhanced the activation and killing ability of T cells. In addition, it exhibited excellent in vivo antitumor activity, making it a promising candidate for cancer immunotherapy.

JOURNAL OF MEDICINAL CHEMISTRY (2023)

Article Chemistry, Medicinal

Discovery of Pyridinone Derivatives as Potent, Selective, and Orally Bioavailable Adenosine A2A Receptor Antagonists for Cancer Immunotherapy

Chenyu Zhu, Shuyin Ze, Ronghui Zhou, Xinyu Yang, Haojie Wang, Xiaolei Chai, Meimiao Fang, Mingyao Liu, Yonghui Wang, Weiqiang Lu, Qiong Xie

Summary: Recent studies and clinical evidence have shown that adenosine A2A receptor (A2AR) antagonists have great potential in cancer immunotherapy. Through screening, compound 38, a pyridinone derivative, was identified as a potent A2AR antagonist with good stability and high bioavailability. Furthermore, compound 38 effectively enhanced the activation of T cells in vitro and demonstrated excellent antitumor activity in vivo, making it a promising candidate for cancer immunotherapy.

JOURNAL OF MEDICINAL CHEMISTRY (2023)

Review Cell & Tissue Engineering

The role of GPCRs in bone diseases and dysfunctions

Jian Luo, Peng Sun, Stefan Siwko, Mingyao Liu, Jianru Xiao

BONE RESEARCH (2019)

Article Pharmacology & Pharmacy

A betulinic acid derivative SH479 inhibits collagen-induced arthritis by modulating T cell differentiation and cytokine balance

Shijie Chen, Yang Bai, Zhen Li, Kunhang Jia, Yunyun Jin, Bei He, Wen-Wei Qiu, Changsheng Du, Stefan Siwko, Huaqing Chen, Mingyao Liu, Jian Luo

BIOCHEMICAL PHARMACOLOGY (2017)

暂无数据